Illumina

Abu Dhabi has the potential to set a precedent for maternal health across the UAE and beyond, but noninvasive prenatal testing (NIPT) access gaps remain. Our Market Access Director for Asia, Middle East & Africa, Nordin Charafi, teamed up with IQVIA Middle East and Africa to map out opportunities for broader coverage and earlier insights for families. Explore the findings: https://lnkd.in/gTDpmvN8

Let's talk about KRAS. It's one of the most commonly mutated oncogenes in cancer. Matching these patients to targeted therapies in the clinic has been a massive difficulty. That's why we're partnering with global pharma partners to develop companion diagnostics that match patients to targeted therapies. This means targeting the genetic drivers of their cancer, going after the source – not the symptom. Read more about our partnership program at the press release in the comments.

What's your "why?" In this installment of our Share Your Why series, Ciara Allen , Issa Moody, PhD, Miles Rogers and Meagan McLeod share why they bring their A-game to genomics every day. ▶️ Click play below. Then click the link in the comments to read more.

280,000+ whole genomes. One powerful partnership. Alnylam Pharmaceuticals is the latest member to join the AGD to help accelerate their discovery and development of RNAi therapeutics. “We welcome Alnylam to the AGD as our members continue to leverage these data to fuel innovation in novel therapeutics to improve lives of patients everywhere” -Todd Christian, Senior Vice President, Services, Arrays, and Genomic Access. More on our partnership: https://bit.ly/4mgqx9j NashBio

This weekend, a group of Illumina employees will join thousands of participants in Pedal the Cause, an annual St. Louis cycling and fitness challenge that raises funds and awareness for cancer research. Two longtime employees, Aimee Keithly and Elizabeth Boyer, shared that this event is much larger than a ride for them – it’s a way to honor loved ones and support lifesaving discoveries. As Elizabeth shared, “Cancer touches every family. This event reinforces why we do what we do, and why we work so hard to advance science.” Hear their story: https://bit.ly/41XmVSw

Daniel Diaz discovered Illumina in the final chapter of The Gene. While reading Siddhartha Mukherjee’s book, he realized the company was headquartered just a short drive from his home in Orange County. That discovery sparked a career change for him into bioinformatics—and eventually led him to his current role as a staff bioinformatics engineer. Today, Daniel works on DRAGEN, ensuring the software meets performance metrics with accuracy and speed. As we celebrate #HispanicHeritageMonth, Daniel’s story highlights the importance of visibility, belonging, and the journeys that bring new voices into genomics. Read more about Daniel’s journey: https://lnkd.in/eqRreGxV

Periprosthetic joint infections are among some of the toughest diagnoses. They consume enormous time and resources, often having patients go through multiple surgeries with no clear answers. MicroGenDX recently analyzed 2,000 joint fluid samples and showed NGS detected infections with 76% sensitivity. Compare that to 63% for culture tests and as low as 41% for a qPCR panel. As infectious disease specialists and orthopedic surgeons know, every additional patient diagnosed accurately is a life changed. Read the full story: https://lnkd.in/efu3dGcj

Unprecedented biological insights — unlocked. Illumina Protein Prep merges an innovative aptamer-based proteomics assay with NGS readout and integrated data analysis, delivering a scalable solution that tackles even the most complex questions. See how we’re transforming proteomics research: https://bit.ly/3JQ8dXb

🚨 The wait is over. Illumina Protein Prep launch day is here, following a successful early access program. 9.5k protein targets. 200+ pathways. 1 panel. The broadest proteome coverage available with NGS. A seamless workflow on Illumina platforms with integrated multiomic analysis. ➡️ https://bit.ly/4n8iHiT

CEO Jacob Thaysen, PhD has an unwavering vision for growth - even in the face of uncertainty. From NGS advances to multiomics and clinical adoption, he recently discussed how we continue to unlock what's next for the industry.